Abstract 221P
Background
GEP-NETs constitute a subset of rare neoplasms. Limited accessibility to first-line treatments in our institution underscores the necessity for exploring alternative therapeutic approaches. This retrospective study aims to describe the clinicopathological characteristics and overall survival (OS) in patients diagnosed with advanced GEP-NET treated with TEMCAP at the National Institute of Neoplastic Diseases (INEN).
Methods
A retrospective review was carried out between 2011 and 2021. OS estimates were generated using Kaplan-Meier method, and differences were assessed using the log-rank test. A Cox regression model was used to evaluate any significant covariates of OS.
Results
Median age was 52 years (24-77), female (53.3%). Most common symptoms at diagnosis were abdominal pain n=31(81.6%), rectal bleeding n=12 (31.6%) and weight loss n=9(23.7%). Clinical staging revealed stage IV n=31(81.6%), stage III n=6(15.8%). Primary tumor sites were rectum n=12 (31.6%), pancreas n=11(28.9%), ileum n=3(7.9%), mesentery n=2(5.3%), small intestine n=2(5.3%), appendix n=1(2.6%), and stomach n=1(2.6%), 6(15.8%) cases of liver metastasis of unknown primary origin. Average tumor size of 4.25 cm (2.725-6.25 cm). G1 n=5 (13.2%), G2 n=33 (86.8%), Ki67 <3% n= 5 (13.2%) and Ki67 3%-20% n=33(86.8%). TEMCAP was administered to 35 (92.1%) patients as first-line treatment. Median number of courses was 9 (6-22.8). Response according to RECIST 1.1 criteria was: CR (n=1), PR (n=2), SD (n=16), PD (n=15), and not evaluated (n=4). OS rates for the entire population at 12, 36, and 60 months were 79.6%, 65.8%, and 42%, respectively. Patients with metastasis ≥2 organs had lower OS rates compared to those with metastasis to a single organ (53% vs 88.5%, 39% vs 74.5%, and 26.5% vs 46.1%) at 12, 36, and 60 months, respectively, with a p-value of 0.021.
Conclusions
TEMPCAP appears to be a viable first-line option in patients with advanced GEP-NET in areas where standard therapy is not accessible. A noteworthy 42% OS rate at 60 months was observed. Prospective studies are needed to better understand the behavior of this disease and determine the true value of TEMPCAP as a therapeutic option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.